New combination for her2 positive advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new combination of two targeted drugs (SHR-A1811 and pyrotinib) for HER2-positive breast cancer that has spread or is locally advanced and has grown despite previous treatments. The goal is to see if this combination can shrink tumors and slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- Your breast cancer is HER2-positive (a specific protein that helps cancer cells grow).
- Your cancer is locally advanced (spread to nearby tissue) or metastatic (spread to other parts of the body).
- You have had previous treatment for advanced breast cancer and it did not work or it stopped working, OR you had early-stage treatment that did not completely control the cancer.
- You have not taken pyrotinib for advanced breast cancer, and you have not had certain other types of antibody-drug therapy.
- Your cancer can be measured on a scan, and you are generally able to take care of yourself (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
This trial tests whether taking pyrotinib continuously or intermittently can help people with HER2-positive advanced breast cancer that has spread. It is for those who have already received prior treatment for their advanced disease.
This trial tests a targeted drug called pyrotinib for women with HER2-positive breast cancer that hasn't spread far. It aims to see if adding this drug to standard treatment helps improve outcomes before and after surgery.
This study tests a combination of two targeted medicines for people with advanced non-small cell lung cancer that has a specific HER2 gene change and has progressed after standard treatment. The goal is to see if the combination can shrink tumors or slow cancer growth.
Hear when a new Metastatic Breast Cancer With HER2 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.